Eli Lilly CDR (CAD Hedged)

The Centers for Medicare & Medicaid Services announced the GENEROUS Model, a voluntary pilot program launching in 2026 that will allow participating state Medicaid programs to purchase select drugs at prices aligned with those paid in other developed countries.

Foghorn Therapeutics reported continued progress in its Phase 1 dose escalation trial of FHD-909 for SMARCA4-mutated cancers, primarily targeting non-small cell lung cancer patients.

Nobel Laureate David Baker's lab at the University of Washington has successfully used AI to design antibodies from scratch with atomic precision, compressing discovery timelines from years to weeks.

The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025.

Eli Lilly has discontinued LY3857210, an oral P2X7 receptor inhibitor, after Phase II data failed to meet the company's internal success criteria for chronic pain treatment.

Eli Lilly's tirzepatide franchise, including Zepbound and Mounjaro, generated $10.1 billion in Q3 2024, overtaking Merck's Keytruda as the world's best-selling drug for the first time.

The U.S. FDA released draft guidance proposing to reduce human clinical study requirements for certain biosimilar drugs and treat them more like generic medications to accelerate market availability.

Eli Lilly announced a partnership with NVIDIA to build what it claims will be the "most powerful supercomputer owned and operated by a pharmaceutical company" to accelerate drug discovery through artificial intelligence.

The FDA has approved a single-injection, once-monthly maintenance regimen for Omvoh (mirikizumab-mrkz) in adults with moderately to severely active ulcerative colitis, replacing the previous two-injection regimen.

Eli Lilly announced the acquisition of Adverum Biotechnologies for up to $261.7 million, including its lead gene therapy candidate Ixo-vec for wet age-related macular degeneration.